Rojas-Jiménez José Alberto, Mota-Sanhua Vanessa, Martínez-Castañeda Diana, Moreno-Vázquez Nancy, López-Ríos Sandra, Covarrubias-Cortés Alejandro, Jácome-Mondragón José Antonio, Velázquez-Hernández Blanca
Centro Médico ABC, Clínicas Comunitarias. Ciudad de México, México.
Rev Med Inst Mex Seguro Soc. 2024 Mar 4;62(2):1-8. doi: 10.5281/zenodo.10712022.
In adults with prediabetes, it is estimated that 51.2% have atherogenic dyslipidemia with low HDL cholesterol, not always diagnosed or treated. The present study evaluates a new intervention adding a class I-II histone deacetylase inhibitor (Trichosanthin A) to the standard management of metformin to treat prediabetes and increase HDL cholesterol.
To evaluate the efficacy of Trichosanthin A and prolonged release metformin on the increase in HDL cholesterol in women with prediabetes.
Double-blind randomized controlled trial with lifestyle management. Group 1 with histone I-II deacetylase inhibitor (Trichosanthin A) and extended-release metformin; group 2 with extended-release metformin and group 3 with placebo. The outcome variable HDL cholesterol evaluated at baseline and after 12 weeks. The study included women between 20-65 y.o., body mass index 25.0-34.9 with prediabetes.
The study sample was made up of 104 female patients, average age of 46 years (SD+8.6), average body mass index of 30.9 (SD + 4.14). In the Trichosanthin A and extended-release metformin group, an increase on HDL cholesterol was observed (2.92 mg/dL; p = 0.027).
The histone I-II deacetylase inhibitor (Trichosanthin A) in addition to standard intensive lifestyle treatment and extended-release metformin significantly increases HDL cholesterol.
据估计，在患有糖尿病前期的成年人中，51.2%患有致动脉粥样硬化性血脂异常，即高密度脂蛋白胆固醇水平低，且这种情况并不总是能得到诊断或治疗。本研究评估了一种新的干预措施，即在二甲双胍的标准治疗方案中添加一种I-II类组蛋白去乙酰化酶抑制剂（天花粉蛋白A），以治疗糖尿病前期并提高高密度脂蛋白胆固醇水平。
评估天花粉蛋白A和缓释二甲双胍对糖尿病前期女性患者提高高密度脂蛋白胆固醇水平的疗效。
采用生活方式管理的双盲随机对照试验。第1组使用组蛋白I-II去乙酰化酶抑制剂（天花粉蛋白A）和缓释二甲双胍；第2组使用缓释二甲双胍；第3组使用安慰剂。在基线和12周后评估结局变量高密度脂蛋白胆固醇。该研究纳入了年龄在20 - 65岁、体重指数为25.0 - 34.9的糖尿病前期女性。
研究样本由104名女性患者组成，平均年龄46岁（标准差 + 8.6），平均体重指数30.9（标准差 + 4.14）。在天花粉蛋白A和缓释二甲双胍组中，观察到高密度脂蛋白胆固醇有所升高（2.92mg/dL；p = 0.027）。
除了标准的强化生活方式治疗和缓释二甲双胍外，组蛋白I-II去乙酰化酶抑制剂（天花粉蛋白A）能显著提高高密度脂蛋白胆固醇水平。
